Physician profile
Meng Chen
NPI 1932510112
$41,611.20
in general payments reported to CMS, 2019-2025
40 companies · $20K in 2025
The $20K reported for 2025 was more than what 92% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $1,029 · 2021: $1,983 · 2022: $2,506 · 2023: $3,759 · 2024: $12K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $10K · Consulting Fee: $8,508 · Travel and Lodging: $873 · Education: $66.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,925.00 |
| Food and Beverage | $10,410.00 |
| Consulting Fee | $8,508.00 |
| Travel and Lodging | $872.91 |
| Education | $66.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $18,408.19 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $12,193.27 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,668.80 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $979.15 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $674.69 | 2019-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $644.51 | 2020-2025 | Cuvitru, Eohilia, Takhzyro |
| Pfizer INC. | $631.05 | 2020-2025 | |
| Biocryst US Sales Co., LLC | $630.02 | 2021-2025 | Orladeyo |
| Csl Behring | $607.94 | 2020-2025 | Hizentra, Haegarda, Andembry |
| Optinose US, INC. | $428.09 | 2019-2025 | |
| Amgen INC. | $417.58 | 2022-2025 | Tezspire, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $391.88 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $390.52 | 2019-2023 | Airduo Digihaler |
| Ars Pharmaceuticals Operations, INC. | $284.33 | 2025 | Neffy |
| Octapharma USA, INC. | $280.36 | 2020-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $250.51 | 2019-2024 | Auvi-Q |
| Blueprint Medicines Corporation | $224.36 | 2024-2025 | Ayvakit |
| Alk-Abello, INC | $190.61 | 2020-2023 | Odactra, Grastek |
| Incyte Corporation | $176.80 | 2021-2025 | Opzelura |
| Pharming Healthcare, INC. | $139.37 | 2020-2025 | Ruconest |
| Organon LLC | $125.07 | 2025 | Nexplanon, Vtama |
| Arcutis Biotherapeutics, INC. | $103.92 | 2025 | Zoryve |
| Genentech, INC. | $90.50 | 2025 | Xolair |
| Aimmune Therapeutics, INC. | $82.63 | 2021-2023 | |
| Hospira, INC. | $66.84 | 2024-2025 | |
| Galderma Laboratories, L.P. | $64.74 | 2024-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $63.33 | 2022-2025 | Adbry, Anzupgo |
| Hikma Pharmaceuticals USA | $60.92 | 2022-2025 | Ryaltris |
| Horizon Therapeutics Plc | $56.07 | 2021-2022 | |
| Aytu Biopharma, INC. | $54.04 | 2024-2025 | Karbinal |
| Shire North American Group INC | $49.71 | 2019 | |
| Mylan Pharmaceuticals INC. | $38.84 | 2019 | |
| Genentech USA, INC. | $23.82 | 2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.69 | 2020 | |
| Biocryst Pharmaceuticals, INC. | $19.31 | 2020 | |
| Azurity Pharmaceuticals, INC. | $18.26 | 2025 | Alvesco |
| Cycle Pharmaceuticals INC | $16.19 | 2025 | Sajazir |
| Phadia US INC. | $15.92 | 2024 | Immunocap |
| Abbvie INC. | $15.37 | 2024 | |
| Uswm, LLC | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meng Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.